Trials / Completed
CompletedNCT05934955
A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003)
Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 1839100 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1839100 in healthy male subjects following oral administration of single rising doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 1839100 | BI 1839100 |
| DRUG | Placebo matching BI 1839100 | Placebo matching BI 1839100 |
Timeline
- Start date
- 2023-07-13
- Primary completion
- 2023-09-25
- Completion
- 2023-10-02
- First posted
- 2023-07-07
- Last updated
- 2023-11-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05934955. Inclusion in this directory is not an endorsement.